Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
First Claim
Patent Images
1. A method of reducing cholesterol level or maintaining previously reduced cholesterol level in a human in need of treatment thereof wherein the human comprises VH segment SNP rs56069819, the method comprisingadministering to said human an alirocumab antibody or antibody fragment thereof that specifically binds a human proprotein convertase subtilisin/kexin type 9 (PCSK9) that comprises an amino acid variation;
- (a) wherein the antibody or fragment comprises a VH domain derived from the recombination of a human VH gene segment, human D gene segment and a human JH gene segment, and(b) wherein the VH gene segment of (a) comprises SNP rs56069819; and
wherein(i) the human expresses a PCSK9 comprising said amino acid variation; and
(ii) the human comprises said SNP.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
-
Citations
24 Claims
-
1. A method of reducing cholesterol level or maintaining previously reduced cholesterol level in a human in need of treatment thereof wherein the human comprises VH segment SNP rs56069819, the method comprising
administering to said human an alirocumab antibody or antibody fragment thereof that specifically binds a human proprotein convertase subtilisin/kexin type 9 (PCSK9) that comprises an amino acid variation; -
(a) wherein the antibody or fragment comprises a VH domain derived from the recombination of a human VH gene segment, human D gene segment and a human JH gene segment, and (b) wherein the VH gene segment of (a) comprises SNP rs56069819; and wherein (i) the human expresses a PCSK9 comprising said amino acid variation; and (ii) the human comprises said SNP. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
Specification